• Augmenter la taille
  • Taille par défaut
  • Diminuer la taille

Eli Lilly and Partners

Since 2003, Lilly has worked hand in hand with its partners to prevent multidrug-resistant tuberculosis (MDR-TB) from gaining ground and taking more lives. Now funded by the Eli Lilly and Company Foundation, the Lilly MDR-TB Partnership brings together government leaders, global health organizations, country-level healthcare providers, community and advocacy organizations and other stakeholders to increase the availability of quality-assured medicine used to treat MDR-TB, enhance education for healthcare professionals where the need is greatest, and raise awareness of the disease amongst communities most at risk.

MULTIDRUG-RESISTANT TB

Lilly collaborates with its partner organizations working to improve outcomes for people who have multidrug-resistant tuberculosis (MDR-TB). Formed in 2003, the Lilly MDR-TB Partnership seeks to increase the access and availability of MDR-TB treatments, while also improving education for healthcare professionals and raising awareness amongst communities most at risk.